Teicher Beverly A, Anderson Kenneth C
Division of Cancer Treatment and Diagnosis, National Cancer Institute, Rockville, Maryland.
Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
Clin Cancer Res. 2015 Mar 1;21(5):939-41. doi: 10.1158/1078-0432.CCR-14-2549.
Proteasome inhibitors have a 20-year history in cancer therapy. The first proteasome inhibitor, bortezomib, a breakthrough treatment for multiple myeloma, moved rapidly through development from the bench in 1994 to first FDA approval in 2003. Clinical Cancer Research has chronicled the development of proteasome inhibitors with publication of reports on bortezomib, carfilzomib, and the oral proteasome inhibitor ixazomib (MLN9708).
蛋白酶体抑制剂在癌症治疗领域已有20年的历史。首个蛋白酶体抑制剂硼替佐米，作为多发性骨髓瘤的突破性治疗药物，于1994年从实验室研发起步，迅速发展，并于2003年首次获得美国食品药品监督管理局（FDA）批准。《临床癌症研究》通过发表关于硼替佐米、卡非佐米和口服蛋白酶体抑制剂伊沙佐米（MLN9708）的报告，记录了蛋白酶体抑制剂的发展历程。
